{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T12:53:47Z","timestamp":1787230427095,"version":"build-2736575974"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2009,6,23]],"date-time":"2009-06-23T00:00:00Z","timestamp":1245715200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Gastroenterol"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1038\/ajg.2009.372","type":"journal-article","created":{"date-parts":[[2009,7,4]],"date-time":"2009-07-04T04:32:51Z","timestamp":1246681971000},"page":"2566-2571","source":"Crossref","is-referenced-by-count":49,"title":["Efficacy of Adalimumab in Moderate-to-Severe Pediatric Crohn's Disease"],"prefix":"10.14309","volume":"104","author":[{"given":"Franca","family":"Viola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fortunata","family":"Civitelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Di Nardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Beatrice","family":"Barbato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osvaldo","family":"Borrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Oliva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Cucchiara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2009,6,23]]},"reference":[{"key":"BFajg2009372_CR1","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/S0140-6736(07)60751-X","volume":"369","author":"DC Baumgart","year":"2007","unstructured":"Baumgart DC, Sandborn WJ . Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007;369:1641\u20131657.","journal-title":"Lancet"},{"key":"BFajg2009372_CR2","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1586\/17474124.2.1.105","volume":"2","author":"AB Grossman","year":"2008","unstructured":"Grossman AB, Baldassano RN . Specific considerations in the treatment of pediatric inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2008;2:105\u2013124.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"BFajg2009372_CR3","doi-asserted-by":"publisher","first-page":"354","DOI":"10.3748\/wjg.14.329","volume":"14","author":"DC Baumgart","year":"2008","unstructured":"Baumgart DC . Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol 2008;14:354\u2013377.","journal-title":"World J Gastroenterol"},{"key":"BFajg2009372_CR4","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.bpg.2004.01.002","volume":"18","author":"A Griffiths","year":"2004","unstructured":"Griffiths A . Specificities of inflammatory bowel disease in childhood. Best Pract Res Clin Gastroenterol 2004;18:509\u2013523.","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"BFajg2009372_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1746-6342.2006.03215.x","volume":"25","author":"S Vermeire","year":"2007","unstructured":"Vermeire S, van Assche G, Rutgeerts P . Review article: altering the natural history of Crohn's disease\u2013evidence for and against current therapies. Aliment Pharmacol Ther 2007;25:3\u201312.","journal-title":"Aliment Pharmacol Ther"},{"key":"BFajg2009372_CR6","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1097\/MOG.0b013e3283043596","volume":"24","author":"J Jones","year":"2008","unstructured":"Jones J, Panaccione R . Biologic therapy in Crohn's disease: state of the art. Curr Opin Gastroenterol 2008;24:475\u2013481.","journal-title":"Curr Opin Gastroenterol"},{"key":"BFajg2009372_CR7","first-page":"109","volume":"8","author":"S Desilva","year":"2008","unstructured":"Desilva S, Kaplan G, Panaccione R . Sequential therapies for Crohn's disease: optimizing conventional and biologic strategies. Rev Gastroenterol Disord 2008;8:109\u2013116.","journal-title":"Rev Gastroenterol Disord"},{"key":"BFajg2009372_CR8","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.cgh.2008.03.014","volume":"6","author":"L Peyrin-Biroulet","year":"2008","unstructured":"Peyrin-Biroulet L, Deltenre P, de Suray N et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008;6:644\u2013653.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"BFajg2009372_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/MPG.0b013e31803e171c","volume":"45","author":"L de Ridder","year":"2007","unstructured":"de Ridder L, Benninga MA, Taminiau JA et al. Infliximab use in children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;45:3\u201314.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"BFajg2009372_CR10","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/S1542-3565(04)00238-1","volume":"2","author":"SB Hanauer","year":"2004","unstructured":"Hanauer SB, Wagner CL, Bala M et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004;2:542\u2013553.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"BFajg2009372_CR11","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMoa020888","volume":"348","author":"F Baert","year":"2003","unstructured":"Baert F, Norman M, Vermeire S et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601\u2013608.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"BFajg2009372_CR12","first-page":"S3","volume":"7","author":"EV Loftus","year":"2007","unstructured":"Loftus EV . Biologic therapy in Crohn's disease: review of the evidence. Rev Gastroenterol Disord 2007;7 (Suppl 1): S3\u2013S12.","journal-title":"Rev Gastroenterol Disord"},{"key":"BFajg2009372_CR13","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","volume":"130","author":"SB Hanauer","year":"2006","unstructured":"Hanauer SB, Sandborn WJ, Rutgeerts P et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130:323\u2013333.","journal-title":"Gastroenterology"},{"key":"BFajg2009372_CR14","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1136\/gut.2006.106781","volume":"56","author":"WJ Sandborn","year":"2007","unstructured":"Sandborn WJ, Hanauer SB, Rutgeerts P et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007;56:1232\u20131239.","journal-title":"Gut"},{"key":"BFajg2009372_CR15","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","volume":"132","author":"JF Colombel","year":"2007","unstructured":"Colombel JF, Sandborn WJ, Rutgeerts P et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52\u201365.","journal-title":"Gastroenterology"},{"key":"BFajg2009372_CR16","doi-asserted-by":"publisher","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","volume":"146","author":"WJ Sandborn","year":"2007","unstructured":"Sandborn WJ, Rutgeerts P, Enns R et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab. A randomized trial. Ann Intern Med 2007;146:829\u2013838.","journal-title":"Ann Intern Med"},{"issue":"Suppl 2","key":"BFajg2009372_CR17","first-page":"S23","volume":"7","author":"WJ Sandborn","year":"2007","unstructured":"Sandborn WJ . Clinical perspectives in Crohn's disease. Moving forward with anti-TNF-alpha therapy: current needs and future treatments. Rev Gastroenterol Disord 2007;7 (Suppl 2): S23\u2013S35.","journal-title":"Rev Gastroenterol Disord"},{"key":"BFajg2009372_CR18","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1002\/ibd.20534","volume":"14","author":"JD Noe","year":"2008","unstructured":"Noe JD, Pfefferkorn M . Short-term response to adalimumab in childhood inflammatory bowel disease. Inflamm Bowel Dis 2008;14:1683\u20131687.","journal-title":"Inflamm Bowel Dis"},{"key":"BFajg2009372_CR19","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/MPG.0b013e318174e886","volume":"47","author":"MJ Wyneski","year":"2008","unstructured":"Wyneski MJ, Green A, Kay M et al. Safety and efficacy of adalimumab in pediatric patients with Crohn disease. J Pediatr Gastroenterol Nutr 2008;47:19\u201312.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"S1","key":"BFajg2009372_CR20","first-page":"A-657","volume":"134","author":"JR Rosh","year":"2008","unstructured":"Rosh JR, Lerer T, Markowitz J . Retrospective evaluation of the safety and effect of adalimumab therapy (reseat) in pediatric Crohn's disease. Gastroenterology 2008;134 S1: A-657.","journal-title":"Gastroenterology"},{"key":"BFajg2009372_CR21","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/00054725-200502000-00013","volume":"11","author":"AM Griffiths","year":"2005","unstructured":"Griffiths AM, Otley AR, Hyams J et al. A review of activity indices and end points for clinical trials in children with Crohn's disease. Inflamm Bowel Dis 2005;11:185\u2013196.","journal-title":"Inflamm Bowel Dis"},{"key":"BFajg2009372_CR22","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1097\/MPG.0b013e31805563f3","volume":"44","author":"A Bousvaros","year":"2007","unstructured":"Bousvaros A, Antonioli DA, Colletti RB et al. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America. J Pediatr Gastroenterol Nutr 2007;44:653\u2013674.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"Suppl A","key":"BFajg2009372_CR23","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1155\/2005\/269076","volume":"19","author":"MS Silverberg","year":"2005","unstructured":"Silverberg MS, Satsangi J, Ahmad T et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19 (Suppl A): 5\u201336.","journal-title":"Can J Gastroenterol"},{"key":"BFajg2009372_CR24","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1111\/j.1365-2036.2007.03253.x","volume":"25","author":"J Seiderer","year":"2007","unstructured":"Seiderer J, Brand S, Dambacher J . Adalimumab in patients with Crohn's disease\u2014safety and efficacy in an open-label single centre study. Aliment Pharmacol Ther 2007;25:787\u2013796.","journal-title":"Aliment Pharmacol Ther"},{"key":"BFajg2009372_CR25","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1111\/j.1572-0241.2004.40462.x","volume":"99","author":"WJ Sandborn","year":"2004","unstructured":"Sandborn WJ, Hanauer S, Loftus EV Jr et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 2004;99:1984\u20131989.","journal-title":"Am J Gastroenterol"},{"key":"BFajg2009372_CR26","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/j.1365-2036.2006.03232.x","volume":"25","author":"J Hinojosa","year":"2007","unstructured":"Hinojosa J, Gomoll\u00f2n N, Garc\u00eca S et al. Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial. Aliment Pharmacol Ther 2007;25:409\u2013418.","journal-title":"Aliment Pharmacol Ther"},{"key":"BFajg2009372_CR27","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.cgh.2006.02.003","volume":"4","author":"P Chamouard","year":"2006","unstructured":"Chamouard P, Richert Z, Meyer N et al. Diagnostic value of C-reactive protein for predicting activity level of Crohn's disease. Clin Gastroenterol Hepatol 2006;4:882\u2013887.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"BFajg2009372_CR28","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1517\/14728222.12.5.553","volume":"12","author":"A Kaser","year":"2008","unstructured":"Kaser A, Tilg H . Novel therapeutic targets in the treatment of IBD. Expert Opin Ther Targets 2008;12:553\u2013563.","journal-title":"Expert Opin Ther Targets"},{"key":"BFajg2009372_CR29","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1053\/gast.2001.26279","volume":"121","author":"WA Faubion","year":"2001","unstructured":"Faubion WA, Loftus EV, Harmsen WS et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001;121:255\u2013260.","journal-title":"Gastroenterology"},{"key":"BFajg2009372_CR30","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1053\/gast.2000.18144","volume":"119","author":"J Markowitz","year":"2000","unstructured":"Markowitz J, Grancher K, Kohn N et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000;119:895\u2013902.","journal-title":"Gastroenterology"},{"key":"BFajg2009372_CR31","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.cgh.2006.05.011","volume":"4","author":"J Markowitz","year":"2006","unstructured":"Markowitz J, Hyams J, Mack D et al. Pediatric IBD Collaborative Research Group. Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn's disease. Clin Gastroenterol Hepatol 2006;4:1124\u20131129.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"BFajg2009372_CR32","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1111\/j.1572-0241.2008.01836.x","volume":"103","author":"JD Lewis","year":"2008","unstructured":"Lewis JD, Gelfand JM, Troxel AB et al. Immunosuppressant medications and mortality in inflammatory bowel disease. Am J Gastroenterol 2008;103:1428\u20131435.","journal-title":"Am J Gastroenterol"},{"key":"BFajg2009372_CR33","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.cgh.2006.03.002","volume":"4","author":"GR Lichtenstein","year":"2006","unstructured":"Lichtenstein GR, Feagan BG, Cohen RD et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006;4:621\u2013630.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"BFajg2009372_CR34","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s11894-007-0068-2","volume":"9","author":"A Swaminath","year":"2007","unstructured":"Swaminath A, Kornbluth A . Optimizing drug therapy in inflammatory bowel disease. Curr Gastroenterol Rep 2007;9:513\u2013520.","journal-title":"Curr Gastroenterol Rep"},{"key":"BFajg2009372_CR35","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.dld.2007.07.167","volume":"40","author":"J Markowitz","year":"2008","unstructured":"Markowitz J . Current treatment of inflammatory bowel disease in children. Dig Liver Dis 2008;40:16\u201321.","journal-title":"Dig Liver Dis"},{"key":"BFajg2009372_CR36","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1002\/ibd.20412","volume":"14","author":"J Punati","year":"2008","unstructured":"Punati J, Markowitz J, Lerer T et al. Pediatric IBD Collaborative Research Group. Effect of early immunomodulator use in moderate to severe pediatric Crohn's disease. Inflamm Bowel Dis 2008;14:949\u2013954.","journal-title":"Inflamm Bowel Dis"},{"key":"BFajg2009372_CR37","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1136\/gut.2004.049460","volume":"54","author":"A Kandiel","year":"2005","unstructured":"Kandiel A, Fraser AG, Korelitz BI et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005;54:1121\u20131125.","journal-title":"Gut"},{"key":"BFajg2009372_CR38","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/MPG.0b013e31802f6424","volume":"44","author":"AC Mackey","year":"2007","unstructured":"Mackey AC, Green L, Liang LC et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44:265\u2013267.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"BFajg2009372_CR39","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1002\/ibd.20169","volume":"13","author":"JR Rosh","year":"2007","unstructured":"Rosh JR, Gross T, Mamula P et al. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm Bowel Dis 2007;13:1024\u20131030.","journal-title":"Inflamm Bowel Dis"},{"key":"BFajg2009372_CR40","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1097\/MPG.0b013e31818cf555","volume":"48","author":"S Cucchiara","year":"2009","unstructured":"Cucchiara S, Escher JC, Hildebrand H et al. Pediatric inflammatory bowel diseases and the risk of lymphoma: should we revise our treatment strategies? J Pediatr Gastroenterol Nutr 2009;48:257\u2013267.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"BFajg2009372_CR41","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1053\/j.gastro.2008.03.004","volume":"134","author":"G Van Assche","year":"2008","unstructured":"Van Assche G, Magdelaine-Beuzelin C, D'Haens G et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008;134:1861\u20131868.","journal-title":"Gastroenterology"}],"container-title":["The American Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ajg2009372.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg2009372","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/ajg.2009.372","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/ajg2009372.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T11:26:54Z","timestamp":1643196414000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000434-200910000-00025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,23]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["BFajg2009372"],"URL":"https:\/\/doi.org\/10.1038\/ajg.2009.372","relation":{},"ISSN":["0002-9270","1572-0241"],"issn-type":[{"value":"0002-9270","type":"print"},{"value":"1572-0241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6,23]]}}}